Lerdelimumab

Modify Date: 2024-07-25 12:00:30

Lerdelimumab structure	Common Name	Lerdelimumab
	CAS Number	285985-06-0	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Lerdelimumab

Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2].

Name	Monoclonal antibody 6B1 igg4

Description	Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2].
Related Catalog	Signaling Pathways >> Stem Cell/Wnt >> TGF-beta/Smad Signaling Pathways >> TGF-beta/Smad >> TGF-beta/Smad Research Areas >> Neurological Disease
In Vitro	Lerdelimumab (10 μg/mL) 抑制 TGF-β2 诱导的所有作用，如：抑制 TGF-β2 刺激被膜袋转分化和收缩，诱导被膜袋的 MMP-2 和 -9 的释放[2]。
In Vivo	Lerdelimumab (100 μL，1 mg/mL；结膜下注射；在术后第 2、3、4、7、9、11 和 14 天) 明显改善青光眼手术结果，降低角膜副作用的风险[1]。
References	[1]. Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401. [2]. Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci.

No Any Chemical & Physical Properties